Vision
Leadership in photodynamic technology.
Mission
To bring innovative solutions to patients and consumers worldwide through efficient development and commercialisation of photodynamic therapy.
Strategy
Photocure has a strong academic network and has a proven track record in development, registration and commercialisation of the products: Metvix® and Hexvix®. Key elements of the company strategy are:
- Build a speciality pharma company
- Maximise the potential of the company's Photodynamic Technology Platform
- Leverage on experience to develop, register and commercialise new products in
- Dermatology:
- Continue the development of the dermatology portfolio, with Allumera® and Visonac® and other new dermatology products, and build a commercial platform in the US
- Cancer:
- Continue the commercialisation of Hexvix® for bladder cancer diagnostics
- Continue the development of the cancer portfolio and out-license prior to phase III studies
This strategy is based on a strong platform of intellectual property in photodynamic technology